Elevian’s Launch to Develop Medicines for Longevity and Age-Related Disorders

 Elevian’s Launch to Develop Medicines for Longevity and Age-Related Disorders

Elevian’s Launch to Develop Medicines for Longevity and Age-Related Disorders

Shots:

  • Elevian generated a seed funding of $5.5M from investors including WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital among others
  • Its founders focus on regenerative effects of young blood and identified a specific circulating factor GDF11, by experimenting circulatory systems of young and old mice and observed regeneration of many tissues and organs in the old mice after 30 days
  • GDF11 (a growth differentiation factor 11) reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, improves exercise capacity and brain function. Elevian will focus on is CAD, Alzheimer disease, T2D and sarcopenia, an age-related muscle dysfunction disorder

Click here to read full press release/ article | Ref: Elevian | Image: Elevian

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post